Pines Wealth Management LLC Purchases New Shares in Sanofi (NASDAQ:SNY)

Pines Wealth Management LLC acquired a new position in Sanofi (NASDAQ:SNY) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 5,072 shares of the company’s stock, valued at approximately $247,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SNY. Northwest Investment Counselors LLC purchased a new position in shares of Sanofi in the 3rd quarter worth approximately $29,000. Concord Wealth Partners boosted its position in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares during the last quarter. Sunbelt Securities Inc. grew its stake in Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the period. Fortitude Family Office LLC increased its position in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after purchasing an additional 659 shares during the last quarter. Finally, UMB Bank n.a. raised its stake in shares of Sanofi by 39.2% during the 3rd quarter. UMB Bank n.a. now owns 1,073 shares of the company’s stock worth $62,000 after purchasing an additional 302 shares during the period. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Performance

NASDAQ:SNY opened at $49.37 on Thursday. The company has a market capitalization of $125.29 billion, a P/E ratio of 25.19, a P/E/G ratio of 1.23 and a beta of 0.57. The business has a fifty day simple moving average of $48.53 and a two-hundred day simple moving average of $52.11. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.55 EPS. On average, analysts expect that Sanofi will post 4.06 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.